0.345

2.54% -0.009

After Hours: .37 0.025 +7.25%

Cyclacel Pharmaceuticals Inc (CYCC)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Cyclacel Pharmaceuticals Inc stock is traded at $0.345, with a volume of 267.19K. It is down -2.54% in the last 24 hours and down -58.53% over the past month. Cyclacel Pharmaceuticals Inc is a clinical-stage biopharmaceutical company that develops targeted medicines for cancer and other proliferative diseases. The company develops several families of anticancer drugs that act on the cell cycle, including CDK (cyclin-dependent kinase) inhibitors, and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include fadraciclib, Sapacitabine, and plogosertib.

Previous Close:

$0.354

Open:

$0.348

24h Volume:

267.19K

Relative Volume:

0.20

Market Cap:

$2.15M

Revenue:

Net Income/Loss:

$-22.56M

P/E Ratio:

-0.1788

EPS:

-1.93

Net Cash Flow:

$-16.12M

1W Performance:

-7.08%

1M Performance:

-58.53%

6M Performance:

-83.17%

1Y Performance:

+19.38%

1-Day Range:

$0.335

$0.355

1-Week Range:

$0.3241

$0.3795

52-Week Range:

$0.231

$4.3785

Cyclacel Pharmaceuticals Inc Stock (CYCC) Company Profile

Name

Cyclacel Pharmaceuticals Inc

Sector

Healthcare (1200)

Industry

Biotechnology (682)

Phone

908-517-7330

Address

200 CONNELL DRIVE, BERKELEY HEIGHTS, NJ

Employee

Twitter

Next Earnings Date

2024-11-11

Latest SEC Filings

CYCC's Discussions on Twitter

Compare CYCC with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CYCC Cyclacel Pharmaceuticals Inc	0.345	2.15M	0	-22.56M	-16.12M	-1.93
VRTX Vertex Pharmaceuticals Inc	464.56	119.70B	10.63B	-479.80M	-1.35B	13.33
REGN Regeneron Pharmaceuticals Inc	754.87	82.75B	13.85B	4.65B	3.32B	35.06
ARGX Argen X Se Adr	614.59	36.73B	1.86B	-40.29M	-1.28B	-4.16
ALNY Alnylam Pharmaceuticals Inc	253.74	32.53B	2.09B	-332.26M	16.06M	-4.14
BNTX Biontech Se Adr	120.72	28.50B	3.30B	-501.07M	1.03B	11.54

Cyclacel Pharmaceuticals Inc Stock (CYCC) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jul-18-22	Resumed	Oppenheimer	Outperform
Apr-27-20	Resumed	ROTH Capital	Buy
Sep-07-18	Initiated	Ladenburg Thalmann	Buy
Oct-16-15	Initiated	H.C. Wainwright	Buy
Feb-04-10	Initiated	Roth Capital	Buy
Oct-28-09	Initiated	Merriman	Buy
Aug-12-08	Initiated	Piper Jaffray	Buy
Mar-12-08	Reiterated	Cantor Fitzgerald	Buy
Mar-12-08	Reiterated	Collins Stewart	Buy
Mar-12-08	Reiterated	Needham & Co	Buy
Nov-27-07	Reiterated	Cantor Fitzgerald	Buy
Aug-10-07	Reiterated	Cantor Fitzgerald	Buy
Jun-04-07	Reiterated	Needham & Co	Buy
Apr-23-07	Initiated	Lazard Capital	Buy
Apr-10-07	Initiated	Cantor Fitzgerald	Buy

View All

Cyclacel Pharmaceuticals Inc Stock (CYCC) Latest News

Nov 26, 2024

Cyclacel Pharmaceuticals, Inc. announced that it expects to receive $2.062112 million in funding - Marketscreener.com

Nov 26, 2024

Nov 24, 2024

Cyclacel Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Nov 24, 2024

Nov 22, 2024

Cyclacel stock plunges to 52-week low of $0.32 amid market challenges By Investing.com - Investing.com South Africa

Nov 22, 2024

Nov 21, 2024

Cyclacel stock plunges to 52-week low of $0.32 amid market challenges - Investing.com

Nov 21, 2024

Nov 18, 2024

Cyclacel Pharmaceuticals Reports Q3 2024 Financial Results - TipRanks

Nov 18, 2024

Nov 15, 2024

Cyclacel Pharmaceuticals Third Quarter 2024 Earnings: EPS Beats Expectations - Yahoo Finance

Nov 15, 2024

Nov 14, 2024

Armistice Capital, LLC Increases Stake in Cyclacel Pharmaceutica - GuruFocus.com

Nov 14, 2024

Cyclacel Pharmaceuticals Announces Closing of Exercise of Warrants for $2.1 Million Gross Proceeds - The Manila Times

Nov 14, 2024

Cyclacel Pharmaceuticals Raises $2.1M Through Warrant Exercise at $0.415 Per Share | CYCC Stock News - StockTitan

Nov 14, 2024